{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:34:04Z","timestamp":1775586844821,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,12,9]],"date-time":"2008-12-09T00:00:00Z","timestamp":1228780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Pompe disease (Glycogen storage disorder type II) is an inherited disease because of a lack or reduced activity of the enzyme \u03b1\u20101,4\u2010glucosidase (acid maltase). Since 2006, an intravenous enzyme replacement therapy (ERT) with Myozyme<jats:sup>\u2122<\/jats:sup> (Genzyme Corporation, Cambridge, MA, USA) is available.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Four adult patients aged between 39 and 68\u2003years received ERT over a period of 6\u2003months. Clinical and functional parameters were registered longitudinally.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> In three patients, a considerable improvement of symptoms could be noticed, patients with pre\u2010existing respiratory insufficiency seemed to profit most. In all patients, a continuous decrease of initially raised laboratory parameters (creatine kinase, lactic dehydrogenase, transaminases) was striking.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Enzyme replacement therapy seems to be a long\u2010term effective therapy in adult patients with Pompe disease. Whether all patients will profit from an improvement of symptoms or at least a stabilisation of the otherwise progressive disease is currently not definitively clear.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2008.02377.x","type":"journal-article","created":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:13:29Z","timestamp":1228868009000},"page":"274-277","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Glycogen storage disease type II (Pompe disease) \u2013 influence of enzyme replacement therapy in adults"],"prefix":"10.1111","volume":"16","author":[{"given":"T.","family":"Merk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wibmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,14]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(95)00115-N"},{"key":"e_1_2_4_3_2","first-page":"304","article-title":"Over idiopathische hypertrofie van het hart","volume":"76","author":"Pompe JC","year":"1932","journal-title":"Nederlands tijdschrift voor geneeskunde"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200367"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2005.05.025"},{"key":"e_1_2_4_6_2","first-page":"3389","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Hirschhorn R","year":"2001"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010383421286"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.5.e448"},{"key":"e_1_2_4_9_2","first-page":"132","article-title":"Recombinant human acid alpha\u2010glucosidase enzyme therapy for infantile glycogen storage disease type II. Results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano A","year":"2001","journal-title":"Genetics in medicine: official journal of the American College of Medical Genetics"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.10.009"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-837543"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20019"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00063-007-1070-z"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/522236"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2008.02377.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2008.02377.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T20:41:59Z","timestamp":1696884119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2008.02377.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,14]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1468-1331.2008.02377.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02377.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,14]]},"assertion":[{"value":"2009-01-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}